Cargando…

Outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality

BACKGROUND AND AIM: As the clinical course of metabolic‐associated fatty liver disease (MAFLD) is unclear, we compared the clinical courses of MAFLD and non‐alcoholic FLD (NAFLD). METHODS: Asian FLD patients (n = 987) from 1991 to 2021 (biopsy‐proven in 939) were enrolled. The patients were divided...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogasawara, Yuri, Kogiso, Tomomi, Horiuchi, Kentaro, Taniai, Makiko, Tokushige, Katsutoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290268/
https://www.ncbi.nlm.nih.gov/pubmed/37359113
http://dx.doi.org/10.1002/jgh3.12898
_version_ 1785062457919668224
author Ogasawara, Yuri
Kogiso, Tomomi
Horiuchi, Kentaro
Taniai, Makiko
Tokushige, Katsutoshi
author_facet Ogasawara, Yuri
Kogiso, Tomomi
Horiuchi, Kentaro
Taniai, Makiko
Tokushige, Katsutoshi
author_sort Ogasawara, Yuri
collection PubMed
description BACKGROUND AND AIM: As the clinical course of metabolic‐associated fatty liver disease (MAFLD) is unclear, we compared the clinical courses of MAFLD and non‐alcoholic FLD (NAFLD). METHODS: Asian FLD patients (n = 987) from 1991 to 2021 (biopsy‐proven in 939) were enrolled. The patients were divided into NAFLD (N‐alone, n = 92), both MAFLD and N (M&N, n = 785), and M‐alone (n = 90) groups. Clinical features, complications, and survival rates were compared among the three groups. Risk factors of mortality were subjected to Cox regression analysis. RESULTS: The N‐alone group patients were significantly younger (N alone, M&N, and M alone: 50, 53, and 57 years, respectively), more frequently male (54.3%, 52.6%, and 37.8%), and had a low body mass index (BMI, 23.1, 27.1, and 26.7 kg/m(2)) and FIB‐4 index (1.20, 1.46, and 2.10). Hypopituitarism (5.4%) and hypothyroidism (7.6%) were significantly observed in the N‐alone group. Hepatocellular carcinoma (HCC) developed in 0.0%, 4.2%, and 3.5% of the cases, and extrahepatic malignancies in 6.8%, 8.4%, and 4.7% of the cases, respectively, with no significant differences. The cardiovascular event rate was significantly higher in the M‐alone group (1, 37, and 11 cases, P < 0.01). Survival rates were similar among the three groups. Risk factors for mortality were age and BMI in the N‐alone group; age, HCC, alanine transaminase, and FIB‐4 in the M&N group; and FIB‐4 in the M‐alone group. CONCLUSION: Different risk factors for mortality may exist among the FLD groups.
format Online
Article
Text
id pubmed-10290268
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wiley Publishing Asia Pty Ltd
record_format MEDLINE/PubMed
spelling pubmed-102902682023-06-25 Outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality Ogasawara, Yuri Kogiso, Tomomi Horiuchi, Kentaro Taniai, Makiko Tokushige, Katsutoshi JGH Open Original Articles BACKGROUND AND AIM: As the clinical course of metabolic‐associated fatty liver disease (MAFLD) is unclear, we compared the clinical courses of MAFLD and non‐alcoholic FLD (NAFLD). METHODS: Asian FLD patients (n = 987) from 1991 to 2021 (biopsy‐proven in 939) were enrolled. The patients were divided into NAFLD (N‐alone, n = 92), both MAFLD and N (M&N, n = 785), and M‐alone (n = 90) groups. Clinical features, complications, and survival rates were compared among the three groups. Risk factors of mortality were subjected to Cox regression analysis. RESULTS: The N‐alone group patients were significantly younger (N alone, M&N, and M alone: 50, 53, and 57 years, respectively), more frequently male (54.3%, 52.6%, and 37.8%), and had a low body mass index (BMI, 23.1, 27.1, and 26.7 kg/m(2)) and FIB‐4 index (1.20, 1.46, and 2.10). Hypopituitarism (5.4%) and hypothyroidism (7.6%) were significantly observed in the N‐alone group. Hepatocellular carcinoma (HCC) developed in 0.0%, 4.2%, and 3.5% of the cases, and extrahepatic malignancies in 6.8%, 8.4%, and 4.7% of the cases, respectively, with no significant differences. The cardiovascular event rate was significantly higher in the M‐alone group (1, 37, and 11 cases, P < 0.01). Survival rates were similar among the three groups. Risk factors for mortality were age and BMI in the N‐alone group; age, HCC, alanine transaminase, and FIB‐4 in the M&N group; and FIB‐4 in the M‐alone group. CONCLUSION: Different risk factors for mortality may exist among the FLD groups. Wiley Publishing Asia Pty Ltd 2023-05-22 /pmc/articles/PMC10290268/ /pubmed/37359113 http://dx.doi.org/10.1002/jgh3.12898 Text en © 2023 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Ogasawara, Yuri
Kogiso, Tomomi
Horiuchi, Kentaro
Taniai, Makiko
Tokushige, Katsutoshi
Outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality
title Outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality
title_full Outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality
title_fullStr Outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality
title_full_unstemmed Outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality
title_short Outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality
title_sort outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290268/
https://www.ncbi.nlm.nih.gov/pubmed/37359113
http://dx.doi.org/10.1002/jgh3.12898
work_keys_str_mv AT ogasawarayuri outcomesoffattyliverdiseasewithandwithoutmetaboliccomorbiditiesandriskfactorsformortality
AT kogisotomomi outcomesoffattyliverdiseasewithandwithoutmetaboliccomorbiditiesandriskfactorsformortality
AT horiuchikentaro outcomesoffattyliverdiseasewithandwithoutmetaboliccomorbiditiesandriskfactorsformortality
AT taniaimakiko outcomesoffattyliverdiseasewithandwithoutmetaboliccomorbiditiesandriskfactorsformortality
AT tokushigekatsutoshi outcomesoffattyliverdiseasewithandwithoutmetaboliccomorbiditiesandriskfactorsformortality